We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01375764
First Posted: June 17, 2011
Last Update Posted: December 23, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Amgen
Results First Submitted: September 2, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab
Drug: Ezetimibe
Other: Placebo to Evolocumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

The study enrolled adults aged 18 to 75 years with hypercholesterolemia who were statin intolerant and with low-density lipoprotein cholesterol (LDL-C) levels above risk-based goals recommended by the National Cholesterol Education Program.

The first patient enrolled on 28 July 2011; last patient enrolled 14 February 2012.


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Randomization was stratified by screening LDL-C level (< 130 mg/dL [3.4 mmol/L] or ≥ 130 mg/dL) and statin use at baseline (yes or no).

Reporting Groups
  Description
Ezetimibe Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
Evolocumab + Ezetimibe Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
Evolocumab 280 mg Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Evolocumab 350 mg Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Evolocumab 420 mg Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Participant Flow:   Overall Study
    Ezetimibe   Evolocumab + Ezetimibe   Evolocumab 280 mg   Evolocumab 350 mg   Evolocumab 420 mg
STARTED   33   31   32   32   32 
Received Treatment   32   30   32   31   32 
COMPLETED   31   30   32   31   31 
NOT COMPLETED   2   1   0   1   1 
Lost to Follow-up                0                1                0                0                0 
Withdrawal by Subject                2                0                0                0                1 
Other                0                0                0                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full analysis set (all randomized participants who received at least 1 dose of investigational product).

Reporting Groups
  Description
Ezetimibe Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
Evolocumab + Ezetimibe Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
Evolocumab 280 mg Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Evolocumab 350 mg Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Evolocumab 420 mg Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Total Total of all reporting groups

Baseline Measures
   Ezetimibe   Evolocumab + Ezetimibe   Evolocumab 280 mg   Evolocumab 350 mg   Evolocumab 420 mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 32   30   32   31   32   157 
Age 
[Units: Years]
Mean (Standard Deviation)
 62.4  (6.6)   62.0  (7.2)   62.2  (10.1)   62.3  (9.1)   60.0  (8.6)   61.8  (8.4) 
Gender 
[Units: Participants]
           
Female   18   23   18   21   20   100 
Male   14   7   14   10   12   57 
Race/Ethnicity, Customized 
[Units: Participants]
           
American Indian or Alaska Native   0   0   0   0   0   0 
Asian   2   5   1   0   0   8 
Black or African American   2   1   2   2   1   8 
Native Hawaiian or Other Pacific Islander   0   0   0   0   1   1 
White   28   24   28   29   30   139 
Other   0   0   1   0   0   1 
Race/Ethnicity, Customized 
[Units: Participants]
           
Hispanic or Latino   2   0   0   0   0   2 
Not Hispanic or Latino   30   30   32   31   32   155 
Stratification Factor: LDL-C Level 
[Units: Participants]
           
< 130 mg/dL   2   1   2   2   2   9 
≥ 130 mg/dL   30   29   30   29   30   148 
Stratification Factor: Baseline Use of Statin 
[Units: Participants]
           
No   26   26   27   27   27   133 
Yes   6   4   5   4   5   24 
LDL-C Concentration 
[Units: mg/dL]
Mean (Standard Deviation)
 182.9  (36.4)   194.4  (60.1)   194.8  (48.1)   190.3  (47.8)   203.5  (60.3)   193.2  (51.0) 
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration 
[Units: mg/dL]
Mean (Standard Deviation)
 213.7  (40.4)   219.8  (60.5)   225.5  (53.3)   222.9  (55.8)   240.6  (63.9)   224.6  (55.3) 
Apolipoprotein B Concentration 
[Units: mg/dL]
Mean (Standard Deviation)
 138.0  (21.7)   138.8  (33.1)   143.0  (30.6)   144.9  (33.9)   150.8  (34.1)   143.2  (30.9) 
Total Cholesterol/HDL-C Ratio 
[Units: Ratio]
Mean (Standard Deviation)
 4.907  (1.553)   5.093  (2.416)   5.287  (1.816)   5.444  (2.308)   6.438  (2.834)   5.438  (2.265) 
Apolipoprotein B/Apolipoprotein A-1 Ratio 
[Units: Ratio]
Mean (Standard Deviation)
 0.841  (0.230)   0.882  (0.332)   0.906  (0.265)   0.916  (0.332)   1.055  (0.388)   0.921  (0.319) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12   [ Time Frame: Baseline and Week 12 ]

2.  Primary:   Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe   [ Time Frame: Baseline and Week 12 ]

3.  Secondary:   Change From Baseline in LDL-C at Week 12   [ Time Frame: Baseline and Week 12 ]

4.  Secondary:   Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe   [ Time Frame: Baseline and Week 12 ]

5.  Secondary:   Percent Change From Baseline in Non-HDL-C at Week 12   [ Time Frame: Baseline and Week 12 ]

6.  Secondary:   Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe   [ Time Frame: Baseline and Week 12 ]

7.  Secondary:   Percent Change From Baseline in Apolipoprotein B at Week 12   [ Time Frame: Baseline and Week 12 ]

8.  Secondary:   Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe   [ Time Frame: Baseline and Week 12 ]

9.  Secondary:   Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12   [ Time Frame: Baseline and Week 12 ]

10.  Secondary:   Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe   [ Time Frame: Baseline and Week 12 ]

11.  Secondary:   Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12   [ Time Frame: Baseline and Week 12 ]

12.  Secondary:   Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe   [ Time Frame: Baseline and Week 12 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Director
Organization: Amgen Inc.
phone: 866-572-6436


Publications:

Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01375764     History of Changes
Other Study ID Numbers: 20090159
First Submitted: June 16, 2011
First Posted: June 17, 2011
Results First Submitted: September 2, 2015
Results First Posted: December 23, 2015
Last Update Posted: December 23, 2015